Stock Markets
Hasbro appoints new leaders for digital gaming, and people officer
![](https://letizo.com/wp-content/uploads/2024/07/hasbro-appoints-new-leaders-for-digital-gaming-and-peopleofficer_66995c07e5e27.jpeg)
PAWTUCKET, R.I. – Hasbro, Inc. (NASDAQ: HAS), a global leader in toys and games, announced the expansion of its Executive Leadership Team with the addition of John Hight as President of Wizards of the Coast and Digital Gaming, and Holly Barbacovi as Chief People Officer. The appointments are part of the company’s strategic focus on enhancing digital experiences and reinforcing its commitment to a people-first culture.
John Hight, known for his significant contributions to the gaming industry, brings over a decade of experience from Blizzard Entertainment, where he managed the Warcraft franchise.
At Hasbro, Hight will oversee the company’s gaming studios and digital licensing agreements, as well as lead the strategy for popular franchises like MAGIC: THE GATHERING and DUNGEONS & DRAGONS. His leadership aims to drive global growth and develop new tabletop and digital experiences, leveraging his expertise in community building and digital gaming.
Holly Barbacovi returns to Hasbro after serving as Chief Operating Officer at Bungie and brings extensive experience in human resources from her previous roles at Amazon (NASDAQ:) Games and Microsoft (NASDAQ:).
As Chief People Officer, Barbacovi will head the global Human Resources organization, focusing on cultivating an inclusive and dynamic work environment aligned with Hasbro’s values. Her track record in enhancing employee engagement and promoting diversity and inclusivity is expected to be instrumental in the company’s ongoing transformation.
Chris Cocks, CEO of Hasbro, expressed enthusiasm for the new appointments, highlighting Hight’s passion for community-centric gaming and Barbacovi’s courageous leadership and pragmatic approach to human resources. These strategic hires reflect Hasbro’s mission to connect generations of fans through storytelling and play, and its commitment to being an inclusive global employer.
Hasbro, recognized for its corporate citizenship, continues to deliver a wide array of play experiences through its diverse portfolio, which includes iconic brands like NERF, TRANSFORMERS, and PEPPA PIG. The company’s purpose-driven approach aims to create joy and community worldwide, one game, one toy, one story at a time.
The information for this article is based on a press release statement from Hasbro, Inc.
In other recent news, Hasbro Inc (NASDAQ:). experienced a series of notable developments. The company’s Q1 2024 results showed a 24% decline in revenue, despite improvements in operational efficiency and a successful shift towards digital gaming.
JPMorgan upgraded Hasbro’s stock from Neutral to Overweight, highlighting the company’s cost efficiency and growth potential in digital gaming. The firm also expressed optimism for Hasbro’s anticipated growth in the latter half of 2024, driven by the Transformers franchise release and merchandising improvements.
Furthermore, Hasbro priced a $500 million public offering of 6.050% notes due in 2034, with net proceeds estimated at $495 million, intended for general corporate use including the redemption or repayment of existing debt.
Citi also revised its outlook on Hasbro, raising the company’s price target to $64 from $52, attributing this to improved financial projections and optimism regarding Hasbro’s digital transformation, although the firm maintained a Neutral rating on Hasbro shares.
These recent developments reflect a strategic shift in Hasbro’s operations, with a focus on digital gaming and operational efficiency. Analysts from JPMorgan and Citi have noted these changes and adjusted their outlooks accordingly.
InvestingPro Insights
As Hasbro, Inc. (NASDAQ: HAS) fortifies its leadership team with key appointments, the company also faces the financial dynamics of the market. With a market capitalization of 8.45 billion USD, Hasbro’s financial performance indicates a complex picture. The company’s Price to Earnings (P/E) Ratio stands at -6, reflecting market skepticism about its current earnings. However, looking ahead, the adjusted P/E Ratio for the last twelve months as of Q1 2024 is 77.99, suggesting that investors may be expecting future earnings growth.
Despite the challenges, Hasbro’s commitment to dividend payments remains steadfast, having maintained them for 44 consecutive years, with the current dividend yield at 4.62%. This long-standing record of dividend payments underscores the company’s dedication to returning value to shareholders, aligning with its strategic focus on growth and stability.
Moreover, Hasbro’s stock has experienced a significant price uptick over the last six months, with a 30.5% total return, reflecting a positive market sentiment that may be tied to strategic initiatives and leadership changes.
InvestingPro Tips highlight that while analysts anticipate a sales decline in the current year, they also predict the company will be profitable this year. Hasbro is trading at a high Price / Book multiple of 8.4, which could imply that the stock is valued for more than just its net assets, possibly due to the brand’s strength and intellectual property.
For investors and analysts seeking a deeper dive into Hasbro’s financials and future projections, additional tips are available on InvestingPro. Use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, and discover the 13 additional InvestingPro Tips that could further inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Five9 stock hits 52-week low at $28.74 amid market challenges
![](https://letizo.com/wp-content/uploads/2024/09/five9-stock-hits-52-week-low-at-28-74-amid-marketchallenges_66db470e2f7bf.jpeg)
In a turbulent market environment, Five9 (NASDAQ:) Inc’s stock has touched a 52-week low, reaching a price level of $28.74. This significant downturn reflects a broader trend for the cloud software company, which has seen its shares plummet by -58.79% over the past year. Investors are closely monitoring Five9’s performance as it navigates through a period of heightened volatility and shifting industry dynamics, which have contributed to the stock’s current valuation at this low point. The company’s efforts to rebound from this position will be under scrutiny in the coming quarters as market participants look for signs of a strategic turnaround or further indications of market pressures.
In other recent news, Five9 Inc . has achieved an annual revenue run rate exceeding $1 billion in Q2, a significant milestone despite lowering its annual revenue guidance by 3.8% due to customer budget constraints. The company’s adjusted EBITDA margin rose to 17% of revenue, contributing to a strong operating cash flow of $126 million. The company also confirmed plans to reduce its global workforce by approximately 7% by the end of 2024, a strategic move projected to cost between $12 million and $15 million.
Five9’s recent acquisition of Acqueon, a firm specializing in proactive outbound omnichannel customer engagement, aims to expand its AI offerings and bolster its growth. This move is in line with the company’s focus on managing expenses and improving profitability, with initiatives like FedRAMP and expansion into India anticipated to improve gross margins.
In their analysis, Piper Sandler maintained an Overweight rating for Five9, with a steady price target of $47.00, while Needham and BTIG both maintained a Buy rating with price targets of $48.00 and $45.00 respectively. These ratings reflect the firms’ confidence in Five9’s strategic positioning and potential for growth, despite the current challenges and workforce reduction.
InvestingPro Insights
Amid the current market conditions, Five9 Inc’s recent performance can be put into perspective with select data from InvestingPro. The company’s market capitalization stands at roughly $2.15 billion, indicating the size and scale of the business amidst its challenges. Despite the stock’s decline, analysts are showing a hint of optimism, with 20 analysts having revised their earnings estimates upwards for the upcoming period. This could signal a potential turnaround in sentiment or underlying business performance.
Importantly, Five9’s liquid assets are reported to surpass short-term obligations, suggesting that the company maintains a degree of financial flexibility to navigate its current difficulties. Furthermore, while the stock is trading near its 52-week low, it’s worth noting that the relative strength index (RSI) suggests the stock is in oversold territory, which can sometimes precede a rebound in share price. Investors looking for comprehensive analysis and additional InvestingPro Tips on Five9 can find more insights, including 14 other tips, at https://www.investing.com/pro/FIVN.
In terms of financial health, the company operates with a moderate level of debt and is expected to become profitable this year, according to analysts’ predictions. These elements may offer some solace to investors considering the stock’s substantial price fall over the last year. For those seeking a deeper dive into Five9’s valuation and future prospects, the InvestingPro platform provides a fair value estimate of $45.04, which is considerably higher than the current trading price, suggesting potential undervaluation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
TD Cowen maintains Buy on Terns Pharmaceuticals
![](https://letizo.com/wp-content/uploads/2024/09/td-cowen-maintains-buy-on-terns-pharmaceuticals_66db4713864f7.jpeg)
TD Cowen reiterated its Buy rating on shares of Terns Pharmaceuticals (NASDAQ:TERN), following the company’s investor call. The call was held to manage expectations for the upcoming Phase 1/2 CARDINAL study data for chronic myeloid leukemia (CML). The firm noted the challenges in measuring the efficacy endpoint (EP) due to disease progression and the absence of treatment switch guidelines, which makes major molecular response (MMR) a challenging efficacy endpoint for Phase 1/2 trials.
The interim Phase 1/2 data aims to evaluate descriptive efficacy signals, considering patients’ baseline BCR-ABL levels and treatment history. The analyst highlighted that the once-daily (QD) dosing and the lack of food effect could potentially enhance the quality of life for patients compared to other allosteric tyrosine kinase inhibitors (TKIs).
Terns Pharmaceuticals has been focusing on the development of improved treatment options for CML. The company’s approach to dosing, which does not require food intake, may offer a more convenient alternative for patients, potentially leading to better adherence and outcomes.
The topline data from the 6-month Phase 1/2 CARDINAL study is anticipated to be available in 2025. This data will provide further insights into the treatment’s efficacy and safety, which are critical factors in the ongoing development and potential approval process.
Investors and stakeholders in Terns Pharmaceuticals are expected to closely monitor the progress of the CARDINAL study, as it could have a significant impact on the company’s future prospects and position in the CML treatment landscape.
In other recent news, Terns Pharmaceuticals has experienced significant developments. The biopharmaceutical company reported robust earnings and revenue results, with Mizuho Securities maintaining an Outperform rating on Terns shares, citing strong enthusiasm for the company’s drug, TERN-701, a potential treatment for chronic myeloid leukemia.
The firm expects the first interim Phase 1 CARDINAL study data for TERN-701 in December.
Terns also announced the appointment of Elona Kogan as its new chief legal officer, a move that underscores the company’s strategic development and pipeline advancement.
The company also secured an extension of its office lease in Foster City, California, through 2027, reflecting Terns Pharmaceuticals’ operational stability and long-term planning.
In terms of clinical trials, Terns has made progress in its ongoing Phase 1 study of TERN-701, with interim findings suggesting the drug can be administered once daily with or without food.
This development, coupled with the forthcoming Phase 1 data for another of Terns’ drugs, TERN-601—an oral GLP-1 receptor agonist for obesity—expected next month, underscores the company’s commitment to innovative therapies.
These recent developments, from financial performance to executive appointments and clinical trials, highlight Terns Pharmaceuticals’ ongoing efforts to advance its strategic objectives and deliver on its mission. The company’s activities are closely watched by investors and industry analysts, including those from Mizuho Securities, who continue to support the company’s potential.
InvestingPro Insights
As Terns Pharmaceuticals (NASDAQ:TERN) navigates the complexities of its Phase 1/2 CARDINAL study, investors are keeping a keen eye on the company’s financial health and stock performance. According to InvestingPro, Terns holds more cash than debt, which is a positive signal for financial stability. Additionally, with five analysts revising their earnings upwards for the upcoming period, there is a sense of optimism about the company’s potential performance.
However, it’s important to note that Terns is not currently profitable and has been quickly burning through cash, which may raise concerns about long-term sustainability. The company’s P/E Ratio stands at -5.71, reflecting these profitability challenges. Despite these hurdles, Terns has managed a 1 Year Price Total Return of 45.42%, indicating some investor confidence in the company’s growth prospects. The anticipated fair value from analysts stands at 15 USD, while the InvestingPro Fair Value is calculated at 5.8 USD, highlighting a divergence in valuation perspectives.
For those looking for more in-depth analysis, additional InvestingPro Tips on Terns Pharmaceuticals can be found at https://www.investing.com/pro/TERN, offering a comprehensive look at the company’s financial details and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
Macron discussed support for Ukraine and Gaza ceasefire with Germany’s Scholz
![](https://letizo.com/wp-content/uploads/2024/09/macron-discussed-support-for-ukraine-and-gaza-ceasefire-withgermanys-scholz_66db4718bf910.jpeg)
PARIS (Reuters) – French President Emmanuel Macron discussed the importance of maintaining support for Ukraine and the need for a ceasefire in Gaza during talks on Friday with German Chancellor Olaf Scholz, said the French presidency.
Regarding Ukraine, the two leaders expressed their determination to support the country “for as long and as intensively as necessary” in its war against Russia, the Elysee said.
- Forex2 years ago
Forex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Forex2 years ago
Unbiased review of Pocket Option broker
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Stock Markets2 years ago
Morgan Stanley: bear market rally to continue
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China